Systemic Review of Qingkailing Injection of Treatment for Acute Ischemic Stroke

Abstract:

Objective: To evaluate systematically the clinical efficacy and safety of Qingkailing injection (QKL) for treatment of acute ischemic stroke. Method: Randomized controlled trials (RCTs) about QKL for acute ischemic stroke were searched systemically and comprehensively. Two reviewers assessed the quality of the included studies by the Cochrane risk of bias, and extracted the information from the included studies independently. Meta-analysis was conducted with the software Review Manager 5.2.Result: A total of 8 studies with 633 participants were included, and the quality of the studies was relatively low, which only one study used the random number table to generate random sequence. Meta-analysis, the results of QKL group were significantly superior to the west conventional therapy group in the total effective rate [RR=1.28, 95%CI (1.18, 1.39), P<0.000 01], and the mortality rate [RR=0.32, 95%CI (0.11, 0.91), P=0.03], and the degree of neurological damage [MD=-5.61, 95%CI (-8.51,-2.72), P=0.000 1]. It also can inhibit the tumor factor (TNF-α) [MD=-5.56, 95%CI (-9.23,-1.90), P=0.003] and interleukin-6 (IL-6), decrease the index of viscosity of whole blood, suppress the expression of platelet cytosolic-alpha particle membrane glycoprotein CD62P [MD=-2.07, 95%CI (-2.53,-1.61), P<0.000 01], and so on. There were 4 studies mentioned clearly on adverse drug reactions (ADR), and 1 study reported 8 ADRS, 3 of which in the Cxperiment group. Conclusion: Comparing with the control group QKL combined with the conventional therapy was relatively effective and safe, which was based on the systematic review, and the more qualified RCTs are needed to make further study.